Table 1 Clinical characteristics of critically ill COVID‐19‐infected patients with putative invasive pulmonary aspergillosis Patient 1 Patient 2 Patient 3 Patient 4 Age (y) 82 79 77 77 Gender Male Male Male Male Comorbid conditions Hypertension No Yes No No Diabetes No No No Yes Coronary artery disease No Yes No No Chronic obstructive pulmonary disease Yes No No No History of cerebrovascular accident No Yes No No History of cancer Yes Yes No No Dementia No No No No Timing of positive culture for Aspergillus fumigatus (hospital day) Day 15 and 20 Day 7, 10, and 16 Day 10 and 14 Day 10 Clinical features at Aspergillus isolation Fever No No Yes No Respiratory status at Aspergillus isolation IMV IMV IMV IMV New radiographic abnormalities on chest CT or X‐ray Worsening infiltrates Opacities with dense consolidations Cavitary pneumonia Diffuse interstitial and patchy hazy opacities White blood cell count (103/μL) 32.9 21.1 20.1 20.2 Platelet count (103/μL) 376 146 420 123 Procalcitonin (ng/mL) 0.16 0.30 3.30 9.34 Lactic acid (mmol/L) 1.0 3.6 1.6 3.7 Total bilirubin (mg/dL) 2.4 1.1 1.4 2.9 Serum creatinine (mg/dL) 2.6 3.1 1.5 4.1 Serum galactomannan NA 0.71 Negative Negative Vasopressor support Yes Yes Yes Yes Inpatient medications Glucocorticoids Cumulative dose in prednisone equivalent (mg) 932 1000 870 87 Starting date (hospital day) Day 8 Day 2 Day 2 Day 10 Duration (d) 10 10 12 3 Tocilizumab No Yes No No Antibiotics Cefepime + Vancomycin Cefepime + Vancomycin Meropenem + Vancomycin Cefepime + Vancomycin Antifungal therapy Voriconazole Voriconazole Voriconazole Caspofungin Abbreviations: IMV, invasive mechanical ventilation; NA, not available. John Wiley & Sons, Ltd This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.